| 21.03 -0.33 (-1.54%) | 12-26 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term | |
|||
| Targets | 6-month : | 26.33 | 1-year : | 30.76 |
| Resists | First : | 22.54 | Second : | 26.33 |
| Pivot price | 21.24  |
|||
| Supports | First : | 18.89 |
Second : | 16.62 |
| MAs | MA(5) : | 21.07 |
MA(20) : | 20.42 |
| MA(100) : | 16.52 |
MA(250) : | 0 | |
| MACD | MACD : | 0.9 |
Signal : | 1 |
| %K %D | K(14,3) : | 66.2 |
D(3) : | 72.2 |
| RSI | RSI(14): 61.2 |
|||
| 52-week | High : | 22.54 | Low : | 9.11 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.[ KROS ] has closed above bottom band by 38.9%. Bollinger Bands are 23.9% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 21.47 - 21.59 | 21.59 - 21.69 |
| Low: | 20.63 - 20.78 | 20.78 - 20.9 |
| Close: | 20.81 - 21.03 | 21.03 - 21.22 |
Keros Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel treatments for patients suffering from hematological and musculoskeletal disorders with high unmet medical need. The company's lead protein therapeutic product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, and in patients with myelofibrosis. It is also developing small molecule product candidate KER-047 that is being developed for the treatment of anemia, and is currently in Phase 1 clinical trial; and KER-012, which is in Phase 1 clinical trial to treat disorders associated with bone loss, such as osteoporosis and osteogenesis imperfecta, and for the treatment of pulmonary arterial hypertension. The company was incorporated in 2015 and is headquartered in Lexington, Massachusetts.
Tue, 23 Dec 2025
Assenagon Asset Management S.A. Has $4.07 Million Holdings in Keros Therapeutics, Inc. $KROS - MarketBeat
Mon, 22 Dec 2025
Keros Therapeutics (KROS) Upgraded to Strong Buy: Here's Why - Yahoo Finance
Mon, 22 Dec 2025
Here's Why Keros Therapeutics (KROS) Could be Great Choice for a Bottom Fisher - Nasdaq
Sat, 20 Dec 2025
Keros Therapeutics (NASDAQ:KROS) Upgraded at TD Cowen - MarketBeat
Fri, 12 Dec 2025
Keros Therapeutics, Inc. $KROS Shares Sold by OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC - MarketBeat
Fri, 12 Dec 2025
What Makes Keros Therapeutics, Inc. (KROS) a Strong Momentum Stock: Buy Now? - Yahoo Finance
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Neutral |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Outperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 30 (M) |
| Held by Insiders | 1.322e+007 (%) |
| Held by Institutions | 3.6 (%) |
| Shares Short | 5,860 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | 4.793e+007 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 26.1 % |
| Operating Margin | -107.9 % |
| Return on Assets (ttm) | 4.3 % |
| Return on Equity (ttm) | 10.4 % |
| Qtrly Rev. Growth | 3 % |
| Gross Profit (p.s.) | 639.77 |
| Sales Per Share | 2.74133e+008 |
| EBITDA (p.s.) | 1.01956e+008 |
| Qtrly Earnings Growth | 1.5 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | 89 (M) |
| PE Ratio | 0 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | 0 |
| Price to Cash Flow | 1.09 |
| Dividend | 0 |
| Forward Dividend | 3.23e+006 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|